四环医药(00460.HK)旗下抗血栓形成药获批上市

阿斯达克财经06-26

四环医药(00460.HK) 公布，附属弘和制药研发的替格瑞洛分散片获得国家药监局颁发的药品注册批件，可视同通过仿制药质量和疗效一致性评价。弘和制药研发的该产品为国产首家获批上市。该药是一种新型抗血栓形成药，具有强效抗血小板聚预防血栓形成的作用。今次替格瑞洛分散片获批上市，将进一步惠及广大患者，同时为集团的心脑血管领域药物管线再添一重要品种，对集团的经营业绩产生积极影响。(ha/u)(港股报价延迟...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2446538764?lang=zh_CN&edition=full","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20220413154446706_s.jpg","is_english":false,"pubTime":"2024-06-26 12:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2446538764","market":"us","top_or_hot":-1,"title":"四环医药(00460.HK)旗下抗血栓形成药获批上市","media":"阿斯达克财经","content":"<div>\n<p>四环医药(00460.HK) 公布，附属弘和制药研发的替格瑞洛分散片获得国家药监局颁发的药品注册批件，可视同通过仿制药质量和疗效一致性评价。弘和制药研发的该产品为国产首家获批上市。该药是一种新型抗血栓形成药，具有强效抗血小板聚预防血栓形成的作用。今次替格瑞洛分散片获批上市，将进一步惠及广大患者，同时为集团的心脑血管领域药物管线再添一重要品种，对集团的经营业绩产生积极影响。(ha/u)(港股报价延迟...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1359288/latest-news/AAFN\">网页链接</a>\n\n</div>\n","source":"aastocks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>四环医药(00460.HK)旗下抗血栓形成药获批上市</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n四环医药(00460.HK)旗下抗血栓形成药获批上市\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-26 12:01 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1359288/latest-news/AAFN><strong>阿斯达克财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>四环医药(00460.HK) 公布，附属弘和制药研发的替格瑞洛分散片获得国家药监局颁发的药品注册批件，可视同通过仿制药质量和疗效一致性评价。弘和制药研发的该产品为国产首家获批上市。该药是一种新型抗血栓形成药，具有强效抗血小板聚预防血栓形成的作用。今次替格瑞洛分散片获批上市，将进一步惠及广大患者，同时为集团的心脑血管领域药物管线再添一重要品种，对集团的经营业绩产生积极影响。(ha/u)(港股报价延迟...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1359288/latest-news/AAFN\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00460","symbol_name":"四环医药","start_time":0,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1359288/latest-news/AAFN","article_id":"2446538764","we_media_id":null,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20220413154446706_s.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2446538764","pubTimestamp":1719374460,"sourceInfo":{"source_id":"aastocks_highlight","name":"阿思達克財經"},"weMediaInfo":null,"summary":"四环医药(00460.HK) 公布，附属弘和制药研发的替格瑞洛分散片获得国家药监局颁发的药品注册批件，可视同通过仿制药质量和疗效一致性评价。弘和制药研发的该产品为国产首家获批上市。该药是一种新型抗血栓形成药，具有强效抗血小板聚预防血栓形成的作用。今次替格瑞洛分散片获批上市，将进一步惠及广大患者，同时为集团的心脑血管领域药物管线再添一重要品种，对集团的经营业绩产生积极影响。(ha/u)(港股报价延迟最少十五分钟。沽空资料截至 2024-06-25 16:25。)AASTOCKS新闻","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"00460":"四环医药","BK1600":"工业大麻","BK1191":"制药","BK1515":"抗疫概念","BK1593":"医美概念股"},"translate_title":"Sihuan Pharmaceutical (00460. HK) 's antithrombotic drug approved for marketing","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00460":1},"content_text":"四环医药(00460.HK) 公布，附属弘和制药研发的替格瑞洛分散片获得国家药监局颁发的药品注册批件，可视同通过仿制药质量和疗效一致性评价。弘和制药研发的该产品为国产首家获批上市。该药是一种新型抗血栓形成药，具有强效抗血小板聚预防血栓形成的作用。今次替格瑞洛分散片获批上市，将进一步惠及广大患者，同时为集团的心脑血管领域药物管线再添一重要品种，对集团的经营业绩产生积极影响。(ha/u)(港股报价延迟最少十五分钟。沽空资料截至 2024-06-25 16:25。)AASTOCKS新闻","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2446538764"}